Patents Assigned to ANTENGENT THERAPEUTICS LIMITED
  • Ectonucleotidase inhibitors and methods of use thereof
    Patent number: 11858957
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: January 2, 2024
    Assignee: ANTENGENT THERAPEUTICS LIMITED
    Inventors: Lijing Chen, Roland Joseph Billedeau, Jim Li